CAPR Legal Notice: BFA Law Notifies Capricor Therapeutics Investors that Lost Money of the Imminent September 28 Securities Fraud Class Action Deadline

Capricor Therapeutics faces a securities fraud class action lawsuit alleging the company made false statements about its lead product Deramiocel and misrepresented clinical data integrity in its FDA Biologics License Application. The lawsuit was triggered by a 64.5% stock drop on July 27, 2026, following FDA briefing documents that raised concerns about post-hoc changes to the statistical analysis plan. Investors have until September 28, 2026 to request lead plaintiff status.